Universidad Complutense de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.

    REC: CardioClinics, Vol. 59, Núm. 4, pp. 310-321

2023

  1. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  2. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]

    Endocrinologia, Diabetes y Nutricion, Vol. 70, pp. 51-62

2022

  1. Chronic coronary syndrome: practical management of antianginal drugs.

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SE, pp. 1-10

  2. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

2018

  1. Why Should We Recommend Pneumococcal Vaccine in Patients With Chronic Heart Diseases?

    Revista Espanola de Cardiologia, Vol. 71, Núm. 1, pp. 57-58

2010

  1. Antihypertensive efficacy and tolerability oflercanidipine in daily clinical practice. The ELYPSE study

    Russian Journal of Cardiology, Vol. 84, Núm. 4, pp. 72-77

2008

  1. Adverse events in clinical trials: is a new approach needed?

    The Lancet

  2. N-acetylcysteine for the prevention of atrial fibrillation: Beyond its antioxidant effect

    European Heart Journal

2007

  1. Evolution of blood pressure control in Spain [2]

    Journal of Hypertension